Vistagen Therapeutics Appoints New CFO, Discloses Compensation Terms
Vistagen Therapeutics, Inc. (SEC file no. 0001411685) filed an 8-K on October 9, 2026, appointing a new CFO and disclosing compensatory arrangements under Item 5.02 and Item 9.01 (financial statements).
51CFO view：CFO appointment at a public company triggers 8-K filing, 10-K updates, SOX 404 continuity review, and audit committee charter revision. For Chinese pre-IPO firms, this highlights SEC’s intensified scrutiny of executive biographies — requiring verifiable U.S. public company reporting experience and clean PCAOB audit history.
Vistagen Therapeutics, Inc. (SEC file no. 0001411685) filed an 8-K on October 9, 2026, appointing a new CFO and disclosing compensatory arrangements under Item 5.02 and Item 9.01 (financial statements).
Source：SEC EDGAR · 8-K 重大事项公告